ArticleJournal of hepatocellular carcinoma2026
Development of a PNI-Based Prognostic Model for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib-Based Triple Therapy.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prognostic stratification remains suboptimal in unresectable hepatocellular carcinoma (uHCC) treated with locoregional therapy (LRT) plus lenvatinib and PD-1 blockade. Existing staging systems insufficiently reflect host nutritional-immune status. Methods: We included a multicenter retrospective study including 347 patients with uHCC treated with LRT, lenvatinib, and a PD-1 inhibitor. Nine prognostic models were developed using Cox regression Model performance was evaluated using time-dependent AUC (tdAUC), calibration, and decision curve analysis (DCA). A nomogram was constructed for individualized survival prediction. Results: Median overall survival (OS) was 33.1 months (95% CI, 30.5-not reached) and median progression-free survival (PFS) was 10.2 months (95% CI, 9.0-12.6) in the overall cohort. The integrated model (incorporating tumor burden, ALBI grade, AFP, PNI) showed superior discrimination, with C-indices of 0.780 (training cohort) and 0.785 (validation cohort). The tdAUCs for OS and PFS were 0.892 and 0.807, respectively, in the training cohort and 0.861 and 0.819, respectively, in the validation cohort. Calibration plots demonstrated good agreement between predicted and observed 2-year OS in both cohorts. Risk stratification based on tertiles yielded significantly separated survival curves in both cohorts (all P<0.001). The nomogram achieved strong predictive accuracy, with 1-, 2-, and 3-year AUCs of 0.879, 0.808, and 0.787, respectively. Conclusion: PNI-integrated prognostic model provides robust risk stratification for uHCC patients receiving LRT combined with lenvatinib and PD-1 inhibitors, supporting individualized pre-treatment risk assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.